OpGen (LTS:0A8L) Debt-to-EBITDA : -0.95 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is OpGen Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

OpGen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $9.72 Mil. OpGen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.83 Mil. OpGen's annualized EBITDA for the quarter that ended in Sep. 2023 was $-13.27 Mil. OpGen's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.95.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for OpGen's Debt-to-EBITDA or its related term are showing as below:

LTS:0A8L' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.12 Med: -0.22 Max: -0.04
Current: -0.56

During the past 10 years, the highest Debt-to-EBITDA Ratio of OpGen was -0.04. The lowest was -1.12. And the median was -0.22.

LTS:0A8L's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs LTS:0A8L: -0.56

OpGen Debt-to-EBITDA Historical Data

The historical data trend for OpGen's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Debt-to-EBITDA Chart

OpGen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.15

-0.28

-1.12

-0.92

-0.46

OpGen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.29	-0.39	-0.73	-0.67	-0.95

Competitive Comparison of OpGen's Debt-to-EBITDA

For the Medical Devices subindustry, OpGen's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OpGen's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OpGen's Debt-to-EBITDA falls into.

OpGen Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

OpGen's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(7.405	+	7.417)	/	-32.384
	=	-0.46

OpGen's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(9.722	+	2.83)	/	-13.268
	=	-0.95

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

OpGen (LTS:0A8L) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

OpGen Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OpGen's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

OpGen (LTS:0A8L) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

OPGN:USA 650:Germany

Address

9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850

Website

https://www.opgen.com

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen (LTS:0A8L) Headlines

No Headlines